



Ewoud-Jan van Hoogdalem

Ewoud-Jan van Hoogdalem, PhD, PharmD, Vice President, Scientific Affairs, EDS, has 26 years of experience in early clinical drug development for large and small pharmaceutical and biotechnology companies. Importantly, in his position at Johnson & Johnson, Dr van Hoogdalem was the early clinical development leader for their SGLT2 inhibitor program, leading to canagliflozin being the first SGLT2 inhibitor to be approved in the US.

He has worked specifically in clinical Phase 1-3 development for 5 years in a CRO environment, and has supported projects in infectious diseases, metabolic disorders, oncology, bone and cartilage disorders, and rare diseases. Prior to leading PRA's EDS Global Scientific Affairs group, Dr van Hoogdalem established an independent advisory firm focused on strategic drug development (Clinical Reach Drug Development bv). He is a clinical pharmacologist and licensed pharmacist who is fluent in Dutch and English and moderately fluent in French and German. Dr van Hoogdalem has contributed to more than 50 lectures and authored or co-authored more than 30 publications in peer-reviewed journals or book chapters.

About PRA Health Sciences

PRA Health Sciences (PRA) is one of the world's leading global contract research organizations, or CROs, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. Side-by-side with clients, PRA strives to move drug discovery forward to help develop life-saving and life-improving drugs.

PRA has therapeutic expertise in areas that are among the largest in pharmaceutical development, including oncology/hematology, CNS (neurology/psychiatry), cardio-metabolic diseases, inflammation/immunology, infectious diseases, rare diseases, respiratory, and biosimilars.

Since 2000, PRA has performed more than 3,100 clinical trials worldwide and has worked on more than 100 marketed drugs across several therapeutic areas.

With more than 11,000 employees worldwide, PRA's global clinical development platform spans 70+ offices across North America, Latin America, Europe, South Africa, the Middle East, Asia, and Australia.